1. Introduction {#j_med-2016-0099_s_001}
===============

Diabetic nephropathy (DN) is one of the most frequently diagnosed chronic complications in patients with diabetes mellitus. DN is characterized by nephrotic syndromes and diffuse scarring of the glomeruli due to longstanding diabetes mellitus and is a prime reason for dialysis in many developed countries. Published studies have confirmed that persistent proteinuria was an independent risk factor for the progression of diabetic nephropathy \[[@j_med-2016-0099_ref_001],[@j_med-2016-0099_ref_002]\] and that it was also one of the independent important prognostic factors. Therefor, reducing persistent proteinuria has become an important treatment purpose. Many clinical trials have confirmed that the renin angiotensin system and angiotensin II receptor blockers can reduce the levels of urinary protein in patients with DN, thereby delaying its progression. However, only use of angiotensin converting enzyme inhibitor/angiotensin receptor blockers (ARB/ACEI) for treatment of DN was not ideal \[[@j_med-2016-0099_ref_003],[@j_med-2016-0099_ref_004]\]. Several studies \[[@j_med-2016-0099_ref_003]-[@j_med-2016-0099_ref_005]\] have achieved relatively go results for ARB/ACEI combined with tripterygium glycosides in the treatment of DN. However, because a small number of cases were included in each study, the statistical power was limited. Therefore, in this present meta-analysis, we included the openly available published studies and pooled the results to further evaluate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy.

2. Methods {#j_med-2016-0099_s_002}
==========

2.1. Publication searching {#j_med-2016-0099_s_002_s_001}
--------------------------

The associated publication searching procedure was performed by two reviewers independently. Clinical controlled trials comparing tripterygium glycosides plus ARB/ACEI vs. ARB/ACEI alone in the treatment of stage IV diabetic nephropathy were electronically searched in the PubMed and CNKI databases before July 2016. We used the following formula for PubMedand CNKI databases :: ("tripterygium glycosides" OR tripterygium\*) AND ("diabetic nephropathy" OR DN) AND ("clinical efficacy" OR efficacy OR "urinary protein" OR "serum creatinine" OR "liver function damage" OR "gastrointestinal reaction" OR "menstrual disorders") Searches were limited to human trials, with the language restriction of English and Chinese. All references of relevant articles were scanned for additional analysis.

2.2. Inclusion and exclusion criteria {#j_med-2016-0099_s_002_s_002}
-------------------------------------

The patients' inclusion criteria, treatment process, and outcomes of the relevant studies were extracted by two reviewers and then checked by a third reviewer. The patients of the original studies were diagnosed of DN at clinical stage IV; the treatment drug was ACEI/ARB alone or ACEI/ARB plus tripterygium glycosides; The outcomes were restricted to total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity. The exclusion criterias were: case report or review study type; duplicated publications; insufficient data for calculating OR and 95% CI; published in other languages (not Chinese or English).

2.3. Data extraction and quality assessment {#j_med-2016-0099_s_002_s_003}
-------------------------------------------

Data of each included study was extracted by Lan Lejian and Hong Yan independently and cross checked. If disagreement was encountered, the third author (Zhihong Gui) was consulted for consensus. The general information such as journal where the paper was published, the authors of the paper, the year of publication and the treatment methods were extracted from each of the included papers. The results for total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity were extracted by two reviewers independently and cross-checked. The methodological qualities of each included study were evaluated by two reviewers by the Cochrane Reviews Handbook standards.

2.4. Statistical analysis {#j_med-2016-0099_s_002_s_004}
-------------------------

We use Stata 11.0 (<http://www.stata.com>; Stata Corporation, College Station, TX) to do all statistical analyses. Dichotomous data was presented as odds ratio (OR) and its corresponding 95% confidence interval (CI). The measurement data was presented as standard mean difference (SMD). Statistical heterogeneity across the studies was evaluated by the chi-square (*χ*^2^) test\[[@j_med-2016-0099_ref_006]\], and inconsistency was calculated by I^2^\[[@j_med-2016-0099_ref_007]\]. If significant statistical heterogeneity existed among the studies (p\<0.05), the random-effects method was used to pool the data. Otherwise, a fixed-effect method was used. The publication bias was evaluated by Egger's line regression tests and Begg's funnel plot \[[@j_med-2016-0099_ref_013]\].

3. Results {#j_med-2016-0099_s_003}
==========

3.1. Publication characteristics {#j_med-2016-0099_s_003_s_001}
--------------------------------

Two hundred and eleven publications were initially identified through searching the CNKI and PubMed databases. After reading the title, abstract, and full text,197 studies were excluded from this meta-analysis for duplicated publication, without appropriate outcome data. or not being a clinically controlled trial. Finally,14 studies with 992 subjects (512 in the experiment group and 480 in control group) were included in this study ([Figure 1](#j_med-2016-0099_fig_001){ref-type="fig"}). The main characteristics of the included 14 publications \[[@j_med-2016-0099_ref_003]-[@j_med-2016-0099_ref_005], [@j_med-2016-0099_ref_008]-[@j_med-2016-0099_ref_017]\] are shown in [Table 1](#j_med-2016-0099_tab_001){ref-type="table"}.

![The publication searching flow chart.](j_med-2016-0099_fig_001){#j_med-2016-0099_fig_001}

###### 

Main characteristics of the 14 studies

  Study                                      no. Experiment   Control   Treatment                            Course(month)   Outcome                                                                                                                                                               Urine protein
  ------------------------------------------ ---------------- --------- ------------------------------------ --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Cai 2012\[[@j_med-2016-0099_ref_008]\]     32               29        TG 20mg tid+Valsartan 40-80mg/d      3               [^(1)^](#j_med-2016-0099_fn_001){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_002){ref-type="table-fn"}                                                          \>3.5g
  Huang 2010\[[@j_med-2016-0099_ref_009]\]   25               23        TG 20mg tid+ Irbesartan 75-150mg/d   6               [^(1)^](#j_med-2016-0099_fn_003){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_004){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_005){ref-type="table-fn"}   \>3.5g
  Wang 2012\[[@j_med-2016-0099_ref_010]\]    38               19        TG 20mg tid+Valsartan 160mg/d        6               [^(1)^](#j_med-2016-0099_fn_006){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_007){ref-type="table-fn"}                                                          \>1.0g
  Tan 2010\[[@j_med-2016-0099_ref_011]\]     25               23        TG 20mg tid+ Irbesartan 75-150mg/d   6               [^(1)^](#j_med-2016-0099_fn_008){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_009){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_010){ref-type="table-fn"}   \>3.5g
  Song 2005\[[@j_med-2016-0099_ref_012]\]    35               32        TG1mg/kg/d+ Benazepril 5-10mg/d      6               [^(1)^](#j_med-2016-0099_fn_011){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_012){ref-type="table-fn"}                                                          \>1.0g
  Li 2014\[[@j_med-2016-0099_ref_013]\]      26               27        TG1mg/kg/d+Valsartan 80-160mg/d      3               [^(1)^](#j_med-2016-0099_fn_013){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_014){ref-type="table-fn"}                                                          \>3.5g
  Yun 2014\[[@j_med-2016-0099_ref_014]\]     32               29        TG 20mg tid+Valsartan 80-160mg/d     3               [^(1)^](#j_med-2016-0099_fn_015){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_016){ref-type="table-fn"}                                                          \>3.5g
  Li 2013\[[@j_med-2016-0099_ref_015]\]      43               43        TG 20mg tid+Valsartan 80mg/d         3               [^(3)^](#j_med-2016-0099_fn_017){ref-type="table-fn"}                                                                                                                 \>0.5g
  Li 2013\[[@j_med-2016-0099_ref_016]\]      30               30        TG1mg/kg/d+Valsartan 100mg/d         3               [^(1)^](#j_med-2016-0099_fn_018){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_019){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_020){ref-type="table-fn"}   \>0.5g
  Zha0 2011\[[@j_med-2016-0099_ref_017]\]    23               23        TG 20mg tid+Valsartan 160mg/d        1               [^(1)^](#j_med-2016-0099_fn_021){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_022){ref-type="table-fn"}                                                          \>1.5g
  Chen 2013\[[@j_med-2016-0099_ref_003]\]    20               20        TG1mg/kg/d+ Benazepril 20mg/d        1               [^(1)^](#j_med-2016-0099_fn_023){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_024){ref-type="table-fn"}                                                          \>1.5g
  Pu 2013\[[@j_med-2016-0099_ref_004]\]      98               98        TG 20mg tid+Valsartan 80-160mg/d     1               [^(1)^](#j_med-2016-0099_fn_025){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_026){ref-type="table-fn"}                                                          \>0.5g
  Xu 2014\[[@j_med-2016-0099_ref_005]\]      25               25        TG1mg/kg/d+ Benazepril 20mg/d        1               [^(1)^](#j_med-2016-0099_fn_027){ref-type="table-fn"}, [^(2)^](#j_med-2016-0099_fn_028){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_029){ref-type="table-fn"}   \>1.5g
  Chen 2009\[[@j_med-2016-0099_ref_018]\]    60               59        TG1mg/kg/d                           6               [^(1)^](#j_med-2016-0099_fn_030){ref-type="table-fn"}, [^(3)^](#j_med-2016-0099_fn_031){ref-type="table-fn"}                                                          \>1.5g
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3.2. Study quality assessment {#j_med-2016-0099_s_003_s_002}
-----------------------------

The methodological quality of the included each study was evaluated by a six-question instrument. The general qualities of 14 studies were relative poor. Nine studies reported the adequate sequence generation. None of the included studies reported the allocation concealment, were free of selective reporting, of free of other bias. Only one study reported blindness. The outcome of methodological quality of the included 14 studies is shown in [Figure 2](#j_med-2016-0099_fig_002){ref-type="fig"}.

![Quality assessment. (The authors^,^ judgments for each risk of bias item. + indicates low risk, - high risk, ? moderate risk.](j_med-2016-0099_fig_002){#j_med-2016-0099_fig_002}

3.3. Meta-analysis {#j_med-2016-0099_s_003_s_003}
------------------

### 3.3.1. Total efficacy {#j_med-2016-0099_s_003_s_003_s_001}

Eight studies reported the total clinical efficacy between the experiment and control groups. No significant statistical heterogeneity was found in total efficacy (I^2^=24.9%, p\>0.05). Thus, the combined odds ratio (OR)was pooled by a fixed effect model. The pooled OR=4.16 with its 95%CI 2.71\~6.37 (p\<0.05), which indicated the total efficacy of the experiment group was significant higher than that of the control group (p \< 0.05), [Figure 3](#j_med-2016-0099_fig_003){ref-type="fig"}.

![Forest plot of clinical efficacy for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squaresand horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the stud-specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).](j_med-2016-0099_fig_003){#j_med-2016-0099_fig_003}

### 3.3.2. 24h urinary protein {#j_med-2016-0099_s_003_s_003_s_002}

Thirteen studies reported the post-treatment 24h urinary protein quantity. Statistical heterogeneity analysis indicated significant heterogeneity across the studies (I^2^=91.1%, p\<0.05). The data was pooled by a random effect model. The combined standardized mean difference (SMD) was -1.55 with its 95%CI -2.06\~1.03, (p \< 0.05). The results indicated that the 24h urinary protein in the experiment group was significant lower than that of the control group (p \< 0.05), [Figure 4](#j_med-2016-0099_fig_004){ref-type="fig"}.

![Forest plot of 24h urinary protein for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).](j_med-2016-0099_fig_004){#j_med-2016-0099_fig_004}

### 3.3.3. Serum creatinine {#j_med-2016-0099_s_003_s_003_s_003}

Ten studies reported the post-treatment serum creatinine. Significant heterogeneity across the studies existed; it was evaluated by chi-square test (I^2^ = 82.3%, p\<0.05). Thereafter, the data was pooled by a random effect model. The combined standardized mean difference (SMD) was -0.24 with its 95%CI -0.40\<0.09, (p\<0.05). The results indicated that after the treatment, serum creatinine in that experiment group was significant lower than that of the control group (p\<0.05), [Figure 5](#j_med-2016-0099_fig_005){ref-type="fig"}.

![Forest plot of serum creatinine for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).](j_med-2016-0099_fig_005){#j_med-2016-0099_fig_005}

3.4. Toxicity {#j_med-2016-0099_s_003_s_004}
-------------

Eight studies reported tripterygium glycoside-associated toxicity such liver function damage, gastrointestinal reaction, or menstrual disorders. Without statistical heterogeneity among the studies, the data was pooled by a fixed effect model. The pooled OR=6.42 (95%CI: 2.23\~18.48, p\<0.05). The pooled results showed the tripterygium glycoside-associated toxicity incidence was significant higher than that of the control group (p\<0.05), [Figure 6](#j_med-2016-0099_fig_006){ref-type="fig"}.

![Forest plot of tripterygium glycoside-related toxicity for tripterygium glycosides in treatment of stage IV diabetic nephropathy. (The squares and horizontal lines demonstrate the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents the pooled OR and 95% CI).](j_med-2016-0099_fig_006){#j_med-2016-0099_fig_006}

3.5. Publication bias {#j_med-2016-0099_s_003_s_005}
---------------------

Publication bias was evaluated by Begg's funnel plot and Egger's line regression test for each effect size (total efficacy, 24h urinary protein, serum creatinine, and tripterygium glycoside-related toxicity). The Begg's funnel plot for the effect size appears asymmetric at the bottom ([Figure 7](#j_med-2016-0099_fig_007){ref-type="fig"}). However, the Egger's line regression test indicated no publication bias for effect size of total efficacy, 24h urinary protein, and serum creatinine. However, for tripterygium glycoside-related toxicity, the publication bias was significant (t=-3.55, p\<0.05).

![Funnel plot for evaluation the publication bias.(A: total efficacy; B: 24h urinary protein; C: serum creatinine; D: tripterygium glycosides related toxicity)](j_med-2016-0099_fig_007){#j_med-2016-0099_fig_007}

4. Discussion {#j_med-2016-0099_s_004}
=============

Diabetic nephropathy, also known as diabetic kidney disease, is a progressive kidney disease caused by damage to the capillaries in the kidneys' glomeruli \[[@j_med-2016-0099_ref_019]\].The pathogenesis of diabetic nephropathy includes many factors such as hemodynamics, inflammation, oxidative stress, and immune reactions \[[@j_med-2016-0099_ref_020]-[@j_med-2016-0099_ref_022]\]. The clinical symptom of diabetic nephropathy is proteinuria, and renal function gradually decreases. The purposes for treatment for DN were to decrease the progression of kidney damage and control associated complications such as proteinuria, hypoproteinemia, and others. The major treatment modality was angiotensin converting enzyme inhibitor / angiotensin receptor blockers (ARB/ACEI)\[[@j_med-2016-0099_ref_023], [@j_med-2016-0099_ref_024]\]. This treatment can generally reduce proteinuria and retard the progression of DN. Other factors such as controlling high blood pressure, controlling blood sugar levels, and dietary salt intake are also important for the DN management.

Recently, several prospective clinical studies have discussed the clinical efficacy of tripterygium glycosides in treatment of stage IV diabetic nephropathy. Most of the studies showed that ARB/ACEI combined with tripterygium glycosides can improve clinical efficacy, decrease the 24h urinary protein, and serum creatinine. However, the indicators of tripterygium glycoside-associated toxicity, such as nausea and vomiting, anorexia, abdominal distension, and bone marrow suppression was also increased. However, because a small number of cases was included in each study, the statistical power was limited. To further investigate the clinical efficacy and safety of tripterygium glycosides in treatment of stage *IV* diabetic nephropathy, studies must be performed with larger study groups. In our present meta-analysis,14 prospective clinical studies including 992 subjects (512 in experiment group and 480 in congrol group) were included. Eight studies reported the total clinical efficacy between experiment and control groups. The pooled results indicated the total efficacy of the experiment group was significant higher than that of the control group (p\<0.05). This result demonstrated that ARB/ACEI combined with tripterygium glycosides can improve the clinical efficacy by about 4-fold. Thirteen studies reported the post-treatment 24h urinary protein quantity; the combined standardized mean difference (SMD) was -1.55. That result indicated that the after treatment, the 24h urinary protein in the experiment group was significant lower than that of the control group (p\<0.05), showing that ARB/ACEI combined with tripterygium glycosides can significant decrease the 24h urinary protein compared with ARB/ACEI use alone. Ten studies reported the post-treatment serum creatinine. The results indicated that the after treatment, ARB/ACEI combined with tripterygium glycosides can significantly decrease the serum creatinine compared with ARB/ACEI only (p\<0.05); Eight studies reported tripterygium glycoside-associated toxicity such as liver function damage, gastrointestinal reaction, and menstrual disorders. The pooled results showed the tripterygium glycoside-associated toxicity incidence was significant higher than that of the control group (p\<0.05). Thus, the present evidence indicates that tripterygium glycosides combined with ARB/ACEI can improve clinical efficacy, reduce the 24h urinary protein, and serum creatinine as compared with ARB/ACEI treatment only.

Several limitations were also found in this meta-analysis: (1) The general quality of the included studies was poor; (2) Significant statistical heterogeneity existed across the included studies; (3) Only Chinese and English studies were included in this meta-analysis; (4) Significant publication bias was found in this meta-analysis.
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